hyperaldosteronism
HYPERALDOSTERONISM
Hyperaldosteronism is a group of disorders in which aldosterone production is inappropriately high, relatively autonomous & non-suppressible by sodium loading.
Signs & symptoms are nonspecific.
Symptoms are caused by hypertension (eg headache), hypokalemia (eg polyuria, nocturia, muscle cramps & weakness, tetany, paralysis, etc) & metabolic alkalosis.

Principles of Therapy

  • Patients with bilateral adrenal hyperplasia or those unsuitable for surgery is recommended to be treated medically by mineralocorticoid receptor antagonists
    • They appear to be effective in blood pressure control and protection for blood pressure-independent target organ

Pharmacotherapy

Spironolactone
  • First-line agent for the medical treatment of hyperaldosteronism
  • Mineralocorticoid receptor antagonist that acts on the distal portion of the renal tubule as a competitive antagonist of aldosterone and it also increases sodium and water excretion and reduces potassium excretion
  • An androgen receptor antagonist and progesterone agonist
  • Dose-related gynecomastia was observed
  • A small dose of thiazide diuretic, Triamterine, or Amiloride may be given to avoid the side effects of high dose Spironolactone
Eplerenone
  • Alternative to Spironolactone
  • Selective mineralocorticoid antagonist that has no anti-androgen and progesterone agonist effects
  • It should be given twice daily due to its shorter half-life
Amiloride
  • An epithelial sodium channel antagonist that can ameliorate blood pressure and hypokalemia
  • Less efficacious than Spironolactone but may be useful
  • It has no sex steroid-related side effects but no beneficial effects on endothelial function
Angiotensin-converting enzyme (ACE) inhibitor
  • Can be added if hypertension persists
  • For patients with angiotensin II sensitive adenoma or hyperplasia
  • Efficacy in the low plasma renin state may in part reflect the role of even low concentrations of angiotensin II as an aldosterone secretagogue in adrenal hyperplasia
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Roshini Claire Anthony, 07 Nov 2017

Women who are underweight, particularly in their late teens and mid-thirties, may be at risk for early menopause, a recent study found. 

16 Aug 2014

New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.